Linebacker

HUMBL and the Arena Football League (AFL) Launch Innovative Digital Ticketing Program on Blockchain

Retrieved on: 
Tuesday, February 20, 2024
Blockchain, Privacy, OTC, Arena Football League, Fraud, Sale, Commerce, Digital, HBS, Risk, Linebacker, NFT, Trust, VIP, QR, Oregon Ducks, AFL, Cryptocurrency

HUMBL is a digital wallet and web platform company that is the “Official Technology Platform'' of the Arena Football League (AFL) through the 2028 season.

Key Points: 
  • HUMBL is a digital wallet and web platform company that is the “Official Technology Platform'' of the Arena Football League (AFL) through the 2028 season.
  • This new ticketing program, starting first with the Oregon BlackBears, allows fans greater levels of authentication and verification in ticketing through the use of digital wallets and blockchain technology.
  • This innovative HUMBL Tickets program solves these issues through the use of digital wallets and blockchain technology,” said HUMBL CEO Brian Foote.
  • “The AFL is proud to be working with HUMBL Tickets to disrupt the ticketing industry and drive an immersive and digital fan experience in doing so.”

Wendy's Celebrated the Next Generation of Sideline Reporters with the 2023 New York Giants Jr. Reporter Sweepstakes

Retrieved on: 
Tuesday, October 24, 2023
Social media, Giant, Lunch, MetLife Stadium, Washington Commanders, Love, Linebacker, Wendy's, American Dream, Parent

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Long Island native, Alexa Colao won Wendy's® New York Giants Jr. Reporter Sweepstakes and interviewed Giants Wide Receiver Darius Slayton for the team's social media outlets. She and her family enjoyed the ultimate touchdown of prizes which included an exclusive tour of the Giants practice facilities and MetLife Stadium, a signed Daniel Jones helmet, a $500 Wendy's gift card, and four suite level tickets to the Giants game on October 22.

Key Points: 
  • Local Long Island resident, Alexa Colao, won Wendy's New York Giants Jr. Reporter Sweepstakes and received on-field recognition at the October 22 game against the Washington Commanders
    NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Long Island native, Alexa Colao won Wendy's® New York Giants Jr. Reporter Sweepstakes and interviewed Giants Wide Receiver Darius Slayton for the team's social media outlets.
  • The lunch was complete with a surprise appearance by former Giants Linebacker, Jonathan Castillas, who signed autographs, posed for pictures, and answered questions from the kids.
  • All of the kids, with help from their parents or guardian, entered the sweepstakes using an online form via the New York Giants website with winners chosen at random.
  • Wendy's is proud to continue its support of the Jr. Reporter program that gives future sports reporters a giant opportunity to champion their love of reporting on the game.

ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound

Retrieved on: 
Thursday, August 3, 2023
Therapy, LB-1, Cancer, Genomics, Burn, Linebacker, Machine learning, Artificial intelligence, Prophase, Karkus, IND, Pharmaceutical industry, Medical device, Certis Group

“We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.

Key Points: 
  • “We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
  • “Our team is very pleased to be working with ProPhase on the Linebacker initiative.
  • “Savvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward.
  • We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.

ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing

Retrieved on: 
Thursday, June 1, 2023
Charles River Laboratories, LB-1, Baylor College of Medicine, Baylor University, Cell proliferation, Lung cancer, Genomics, Prophase, Harvard University, Lung, Dana–Farber Cancer Institute, Linebacker, HT29, Cancer, Risk, Observation, Dana, Pharmaceutical industry, Vaccine, Doxorubicin

Garden City, NY, June 01, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), as a potential unique therapy option for several poor prognosis cancers.

Key Points: 
  • Harvard scientists at the Dana Farber Cancer Institute, in two separate lung and colon cancer clonogenic models, have successfully demonstrated Linebacker’s ability to inhibit cancer cell growth, an exciting development for the polyphenol compound.
  • Also observed were synergies between Linebacker and low doses of frontline chemotherapeutic agents such as Doxorubicin in the colon cancer model.
  • With proof-of-principle demonstrated, the ProPhase team is moving forward with in-depth cancer modeling to precisely hone-in on optimal clinical pathways for development.
  • We are looking forward to Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

Retrieved on: 
Wednesday, May 3, 2023
LB-1, Enzyme, Cancer, Research, Genomics, Linebacker, Patient, Prophase, FDA, IND, Genome, Pharmaceutical industry

ProPhase was excited to learn that numerous critically important kinase targets were inhibited more than 99%.

Key Points: 
  • ProPhase was excited to learn that numerous critically important kinase targets were inhibited more than 99%.
  • We believe the unique interplay of Linebacker with multiple cancer-dependent pathways will be a true differentiator within current treatment paradigms.
  • In line with these impressive results, Linebacker-1 has demonstrated strong preclinical potential in a number of difficult diseases, including tough-to-treat lung and gastric cancers.
  • We look forward to providing updates in the coming weeks on additional Linebacker pre-clinical studies that are being conducted in parallel.

Global Research and Discovery Group Announces Completion of Research with Impact Biomedical

Retrieved on: 
Tuesday, April 11, 2023
ChromeOS, DiscoverIE Group, Disease, University, Therapy, Potomac Institute for Policy Studies, Patent cliff, Center for Strategic and International Studies, SARS, Biodefense, Research, 3F, COVID, HAVEN, Government, Linebacker, Science, Patent, BioForge, Thompson, Cato Institute, Quantum, Technology transfer, ACE2, Fine chemical, Pharmaceutical industry, Vaccine, Management, Bioplastic

WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.

Key Points: 
  • WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.
  • It is anticipated that the next phase of the research will shift to licensing the Impact Biomedical portfolio to larger pharmaceutical companies for down range development.
  • The end of the active work on this project comes at a key time for Global Research and Discovery, which will shift to identifying potential collaborations for continued research.
  • This becomes an issue since these financial returns are required to support research for newer and more effective biomedical discoveries.

DSS Announces Letter to Shareholders   

Retrieved on: 
Thursday, March 2, 2023
Sentinel, NYSE, EBITDA, USX, Initial public offering, IPO, SHRG, Traction, Public Health Service Global Health Campaign Medal, Marketing, DSS, Health, OTCQB, AMRE, Prophase, Organization, Sale, Investment, Letter, Linebacker, OTC, APB, Growth, Russian American Medical Association, Turnaround ADR, Security (finance), Acquisition, IND, Management, Video game, Risk management, Music, Pharmaceutical industry, Cryptocurrency

ROCHESTER, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to enrich shareholder value, today announced a letter to shareholders.

Key Points: 
  • ROCHESTER, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to enrich shareholder value, today announced a letter to shareholders.
  • In my last letter to shareholders, I said 2022 was forecasted to be a breakout year for DSS.
  • Additionally, through its subsidiaries, Decentralized Sharing Systems and SHRG, DSS provides an array of products and services via various direct to consumer models.
  • Overall, I have tremendous confidence in the future of DSS, and I believe our best days are ahead of us.

ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Retrieved on: 
Monday, February 6, 2023
Breast cancer, CLIA, COVID-19, Prophase, Colon, COVID-19 testing, Harvard Medical School, Linebacker, Genomics, PCR, GMP, Dana–Farber Cancer Institute, Radiation, PIM, Toxicity, Kidney, LB-1, Pharmaceutical industry, Vaccine, Topotecan, IND, Doxorubicin

“We are excited to provide this update on our progress with the Linebacker-1 cancer co-therapy program, a platform which we believe has multi-billion-dollar potential in oncology as well as significant potential in other areas,” commented Ted Karkus, ProPhase Lab’s Chief Executive Officer.

Key Points: 
  • “We are excited to provide this update on our progress with the Linebacker-1 cancer co-therapy program, a platform which we believe has multi-billion-dollar potential in oncology as well as significant potential in other areas,” commented Ted Karkus, ProPhase Lab’s Chief Executive Officer.
  • The ongoing studies are focused on identifying the most effective combination of cancer cell lines and agents with LB-1.
  • Initial focus areas include hepatic, colon and breast cancer, and initial therapy agents include Topotecan and Doxorubicin.
  • The Company estimates that the total cost for development prior to exploring a strategic partner will be $3 - $5 million.

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

Retrieved on: 
Tuesday, November 8, 2022
PCR, Medical physics, Research, Department, Gene, Dana–Farber Cancer Institute, Nature, LB-1, Radiation therapy, Company, Industry, Marketing, Dana, Dietary supplement, Environment, SEC, Cancer, Polymerase chain reaction, Acquisition, RT-PCR, COVID-19, Chromosome, CLIA, Private Securities Litigation Reform Act, Inherited disorders of trafficking, Prophase, Nasdaq, Vegetable, Linebacker, Polyphenol, Dementia, Harvard Medical School, Media relations, FDM, Nano, PIM, Toxicity, Growth, Memory, Central nervous system, Food, Trial of the century, GLOBE, Genomics, University, TK, Laboratory, OTC, Severe acute respiratory syndrome coronavirus 2, Labs, Risk, Nebula Genomics, COVID-19 testing, DNA, NASDAQ, Nano Letters, Publication, Myricetin, Inflammation, Pharmaceutical industry, Medical device, Medicinal plants, MD, Brigham

This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.

Key Points: 
  • This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.
  • ProPhase Labs is eager to explore new avenues for scientific discovery with these talented scientists as we pursue novel pathways for cancer treatment.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.
  • The company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co-therapy.

Impact BioMedical Scientific Partner GRDG Sciences to be Featured in New Documentary

Retrieved on: 
Wednesday, October 19, 2022
Diamond, Quantum, Lists of record labels, Investment management, Cholera, Therapy, Science, R, DSS, OTC, Digital transformation, Solution, Freedom, Escherichia coli, Severe acute respiratory syndrome coronavirus 2, LLC, NYSE, Plastic, Alternative trading organization, Cancer, Prophase, Patent cliff, DARPA, Biomedicine, GLOBE, Leadership, Mission: Impossible, Tuberculosis, Research, NIH, Security (finance), Technology, Thompson, MRSA, COO, IPO, Emmy Awards, Sustainable energy, Biosafety, Partnership, Infection, Drug discovery, Linebacker, Epidemic Intelligence Service, Safety, Tom Denney, COVID-19, Pharmaceutical industry, Toy, Fine chemical, Management, Vaccine, Film, Biotechnology, Rhinovirus

ROCHESTER, N.Y., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of people around the world.

Key Points: 
  • Early in the development process, GRDG began a working relationship with Impact Biomedical, who partnered with GRDG and provided investment capital to support its research.
  • Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
  • Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades.
  • By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno -related diseases.